| scholarly article | Q13442814 |
| P50 | author | Francisco J. Quintana | Q88364866 |
| Rafael J. Najmanovich | Q41488364 | ||
| David Pozo | Q42789806 | ||
| Elena Gonzalez-Rey | Q56754174 | ||
| P2093 | author name string | Rafael Fernandez-Montesinos | |
| Juan Luis Herrera | |||
| P2860 | cites work | Toll-like receptor signalling | Q24570126 |
| Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method | Q25938999 | ||
| Pathogen recognition and innate immunity | Q27861084 | ||
| Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells | Q28142976 | ||
| Structure of the human VIPR2 gene for vasoactive intestinal peptide receptor type 2 | Q28144174 | ||
| Imiquimod: mode of action | Q28260444 | ||
| Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts | Q28274847 | ||
| SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase | Q28364720 | ||
| Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice | Q28589323 | ||
| SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1 | Q29620495 | ||
| Expression profiling of genes regulated by TGF-beta: differential regulation in normal and tumour cells. | Q33281716 | ||
| Modulation of atherosclerosis in mice by Toll-like receptor 2 | Q34063165 | ||
| The significance of vasoactive intestinal peptide in immunomodulation | Q34323695 | ||
| Innate and adaptive immunity in the pathogenesis of atherosclerosis | Q34794757 | ||
| Differential signaling of T cell generation of IL-4 by wild-type and short-deletion variant of type 2 G protein-coupled receptor for vasoactive intestinal peptide (VPAC2) | Q35001530 | ||
| Characterisation of the mouse vasoactive intestinal peptide receptor type 2 gene, Vipr2, and identification of a polymorphic LINE-1-like sequence that confers altered promoter activity | Q35648983 | ||
| Modulation of the phosphoinositide 3-kinase signaling pathway alters host response to sepsis, inflammation, and ischemia/reperfusion injury | Q36470828 | ||
| TLR signaling | Q79715393 | ||
| Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation, partially reversible by VIP | Q79748027 | ||
| Lipoteichoic acid-related molecule derived from the streptococcal preparation, OK-432, which suppresses atopic dermatitis-like lesions in NC/Nga mice | Q79918364 | ||
| Natural and synthetic TLR7 ligands inhibit CpG-A- and CpG-C-oligodeoxynucleotide-induced IFN-alpha production | Q79984758 | ||
| The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide? | Q80500671 | ||
| Therapeutic effects of streptococcal preparation OK-432 on atopic dermatitis-like lesions in NC/Nga mice: possible shift from a Th2- to Th1-predominance | Q80592848 | ||
| New insights into the regulation of TLR signaling. | Q36477962 | ||
| Regulation of immune tolerance by anti-inflammatory neuropeptides | Q36691091 | ||
| Cooperation of Toll-like receptor signals in innate immune defence | Q36743540 | ||
| The antitumoral mode of action of imiquimod and other imidazoquinolines | Q36754557 | ||
| Rapid transit in the immune cells: the role of mRNA turnover regulation. | Q36776927 | ||
| Endogenous anti-inflammatory neuropeptides and pro-resolving lipid mediators: a new therapeutic approach for immune disorders | Q37191369 | ||
| Vasoactive intestinal peptide as a healing mediator in Crohn's disease. | Q37230806 | ||
| Th17 cells in airway diseases | Q37239784 | ||
| Vasoactive intestinal peptide suppresses toll-like receptor 4 expression in macrophages via Akt1 reducing their responsiveness to lipopolysaccharide | Q40003155 | ||
| Nuclear export of NF90 to stabilize IL-2 mRNA is mediated by AKT-dependent phosphorylation at Ser647 in response to CD28 costimulation | Q40032360 | ||
| Exploring the specificity of the PI3K family inhibitor LY294002. | Q40170788 | ||
| The phosphatidylinositol 3-kinase inhibitor LY294002 potently blocks K(V) currents via a direct mechanism | Q40605210 | ||
| Induction of macrophage nitric oxide production by Gram-negative flagellin involves signaling via heteromeric Toll-like receptor 5/Toll-like receptor 4 complexes | Q40641430 | ||
| The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells | Q40726959 | ||
| ERK1/2 mitogen-activated protein kinase selectively mediates IL-13-induced lung inflammation and remodeling in vivo | Q40773539 | ||
| Vasoactive intestinal peptide regulates its receptor expression and functions of human keratinocytes via type I vasoactive intestinal peptide receptors | Q40806912 | ||
| Cutting edge: is vasoactive intestinal peptide a type 2 cytokine? | Q40826712 | ||
| Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun | Q40995215 | ||
| Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. | Q41180007 | ||
| VIP reverses the expression profiling of TLR4-stimulated signaling pathway in rheumatoid arthritis synovial fibroblasts. | Q42435583 | ||
| Fifty-five basal cell carcinomas treated with topical imiquimod: outcome at 5-year follow-up | Q42508531 | ||
| Immune-based disorders: the challenges for translational immunology | Q42789792 | ||
| Selective roles of MAPKs during the macrophage response to IFN-gamma | Q43493592 | ||
| Human plasmacytoid dendritic cell function: inhibition of IFN-alpha secretion and modulation of immune phenotype by vasoactive intestinal peptide | Q43636534 | ||
| Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor | Q43786754 | ||
| Selective loss of gastrointestinal mast cells and impaired immunity in PI3K-deficient mice | Q43933405 | ||
| Variable expression of Toll-like receptor in murine innate and adaptive immune cell lines | Q44119028 | ||
| Time-course expression of Toll-like receptors 2 and 4 in inflammatory bowel disease and homeostatic effect of VIP. | Q46460985 | ||
| VIP balances innate and adaptive immune responses induced by specific stimulation of TLR2 and TLR4. | Q46688090 | ||
| Lipoprotein I, a TLR2/4 ligand modulates Th2-driven allergic immune responses | Q47870445 | ||
| Toll-like receptor 4 or 2 agonists decrease allergic inflammation. | Q47886019 | ||
| International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. | Q47906613 | ||
| A study of novel polymorphisms in the upstream region of vasoactive intestinal peptide receptor type 2 gene in autism | Q50311296 | ||
| Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions. | Q51976721 | ||
| Pivotal advance: vasoactive intestinal peptide inhibits up-regulation of human monocyte TLR2 and TLR4 by LPS and differentiation of monocytes to macrophages. | Q54455716 | ||
| Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: Altered expression and signal in immune cells | Q57307099 | ||
| Il-13 and IFN-gamma: interactions in lung inflammation | Q74244341 | ||
| Regulation of VIP production and secretion by murine lymphocytes | Q77911236 | ||
| Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis | Q79319538 | ||
| P433 | issue | 9B | |
| P921 | main subject | toll-like receptor | Q408004 |
| P304 | page(s) | 3209-3217 | |
| P577 | publication date | 2009-09-01 | |
| P1433 | published in | Journal of Cellular and Molecular Medicine | Q1524063 |
| P1476 | title | Toll-like receptor stimulation differentially regulates vasoactive intestinal peptide type 2 receptor in macrophages. | |
| P478 | volume | 13 |
| Q35094493 | Absence of vasoactive intestinal peptide expression in hematopoietic cells enhances Th1 polarization and antiviral immunity in mice |
| Q36923640 | Emerging neuropeptide targets in inflammation: NPY and VIP |
| Q36073902 | LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b |
| Q47956445 | Lipopolysaccharide regulates biosynthesis of cystathionine γ-lyase and hydrogen sulfide through Toll-like receptor-4/p38 and Toll-like receptor-4/NF-κB pathways in macrophages |
| Q87874504 | Monocytes from Sjögren's syndrome patients display increased vasoactive intestinal peptide receptor 2 expression and impaired apoptotic cell phagocytosis |
| Q39388328 | The Enteric Network: Interactions between the Immune and Nervous Systems of the Gut. |
| Q29248835 | Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions |
| Q54364555 | VPAC1 overexpression is associated with poor differentiation in colon cancer. |
| Q37054934 | VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage |
| Q34238010 | Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions |
Search more.